30 October 2026
RECKITT BENCKISER GROUP PLC
EMTN Programme: Publication of Base Prospectus
Reckitt Benckiser Group plc (the “Company”) today announces that the base prospectus for the £10,000,000,000 Euro Medium Term Note Programme of Reckitt Benckiser Treasury Services plc, guaranteed by the Company, has been published (the “Base Prospectus”).
A copy of the Base Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at and can be downloaded from:
National Storage Mechanism | FCA
and
Contacts
|
Nick Ashworth SVP Investor Relations |
+44(0) 7408 812350 |
|
Catheryn O’Rourke General Counsel & Company Secretary |
+44(0) 1753 217800 |
About Reckitt*:
Reckitt is a world-class consumer health and hygiene company on a mission to deliver better health in more hands, every day. Founded in 1840 in the United Kingdom, Reckitt is home to some of the world’s most trusted and recognised brands across Germ Protection, Household Care, Intimate Wellness and Self Care, including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet.
Operating in more than 80 countries, Reckitt sells approximately 30 million products every day and employs around 36,000 people worldwide. Through trusted brands, science-led innovation and deep consumer understanding, Reckitt helps make health, hygiene and wellbeing more accessible for millions of people while creating sustainable value for consumers, customers, communities and shareholders.
For more information, visit Reckitt at www.reckitt.com.
*Reckitt is the trading name of the Reckitt Benckiser group of companies
Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108
This announcement does not constitute or form part of an offer to sell or the solicitation of an offer to subscribe for or otherwise acquire any securities.
The securities referred to herein and the guarantee thereof have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any State or other jurisdiction of the United States, and are subject to Unites States tax law requirements. Subject to certain exceptions, the securities referred to herein may not be offered, sold or delivered in the United States (as defined in Regulation S under the Securities Act) or to, or for the account or benefit of, U.S. persons (as defined in the U.S. Internal Revenue Code of 1986, as amended, and regulations thereunder). The Base Prospectus may not be accessed from, or transmitted in or into, the United States. Accordingly, these securities may not be offered, sold or delivered in the United States.
Please note that the information contained in the Base Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus is not addressed. Prior to relying on the information contained in the Base Prospectus, you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein. Your right to access this service is conditional upon complying with the above requirements.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.